Our work identified crucial involvement of ACE2 in immunomodulation in luminal A subtype and predict the functional consequence of using ACEIs in this breast cancer subtype, further strengthening the notion that when cancer care and COVID-19 collide, then there is no easy and universal solution to oncologic care. This evidence concerns the gene ACE2 and cancer.